Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Sustained excess BMI increases the risk of type 1 diabetes (T1D) in autoantibody-positive relatives without diabetes of patients. We tested whether elevated BMI also accelerates the progression of islet autoimmunity before T1D diagnosis. RESEARCH DESIGN AND METHODS: We studied 706 single autoantibody–positive pediatric TrialNet participants (ages 1.6–18.6 years at baseline). Cumulative excess BMI (ceBMI) was calculated for each participant based on longitudinally accumulated BMI ≥85th age- and sex-adjusted percentile. Recursive partitioning analysis and multivariable modeling defined the age cut point differentiating the risk for progression to multiple positive autoantibodies. RESULTS: At baseline, 175 children (25%) had a BMI ≥85th percentile. ceBMI range was −9.2 to 15.6 kg/m2 (median −1.91), with ceBMI ≥0 kg/m2 corresponding to persistently elevated BMI ≥85th percentile. Younger age increased the progression to multiple autoantibodies, with age cutoff of 9 years defined by recursive partitioning analysis. Although ceBMI was not significantly associated with progression from single to multiple autoantibodies overall, there was an interaction with ceBMI ≥0 kg/m2, age, and HLA (P = 0.009). Among children ≥9 years old without HLA DR3-DQ2 and DR4-DQ8, ceBMI ≥0 kg/m2 increased the rate of progression from single to multiple positive autoantibodies (hazard ratio 7.32, P = 0.004) and conferred a risk similar to that in those with T1D-associated HLA haplotypes. In participants <9 years old, the effect of ceBMI on progression to multiple autoantibodies was not significant regardless of HLA type. CONCLUSIONS: These data support that elevated BMI may exacerbate islet autoimmunity prior to clinical T1D, particularly in children with lower risk based on age and HLA. Interventions to maintain normal BMI may prevent or delay the progression of islet autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Ogden, C. L., Carroll, M. D., Lawman, H. G., Fryar, C. D., Kruszon-Moran, D., Kit, B. K., & Flegal, K. M. (2016) · JAMA · doi:10.1001/jama.2016.6361 · Cited by 2,178
ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIES
Bottazzo, G., Florin-Christensen, A., & Doniach, D. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90140-8 · Cited by 1,469
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Insulin antibodies in insulin-dependent diabetics before insulin treatment
Palmer, J. P., Asplin, C. M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P. K., & Paquette, T. L. (1983) · Science · doi:10.1126/science.6362005 · Cited by 1,078
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes
Wilkin, T. J. (2001) · Diabetologia · doi:10.1007/s001250100548 · Cited by 623 · cited 2×
“destruction that characterizes T1D (10).”
BackgroundRedondo, M. J., Yu, L., Hawa, M., Mackenzie, T., Pyke, D. A., Eisenbarth, G. S., & Leslie, R. D. G. (2001) · Diabetologia · doi:10.1007/s001250051626 · Cited by 322 · cited 2×
“Although there are several genetic loci for T1D susceptibility, heritability does not completely predict appearance of islet autoantibodies or disease development (2), highlighting the role of other influences such as the environment (3).”
BackgroundSelf-citationWijesekara, N., Krishnamurthy, M., Bhattacharjee, A., Suhail, A., Sweeney, G., & Wheeler, M. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085084 · Cited by 229 · cited 1×
“Moreover, adiponectin has been shown to have direct effects on the b-cells, promoting function and survival (38), further highlighting the adipose tissue as an active participant in T1D pathophysiology, although the nature of the associations is still unclear.”
BackgroundThe Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults
Ferrara, C. T., Geyer, S. M., Evans-Molina, C., Libman, I. M., Becker, D. J., Wentworth, J. M., Moran, A., Gitelman, S. E., Redondo, M. J., & Type 1 Diabetes TrialNet Study Group (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01490 · Cited by 33
Self-citation
Cited by
Pediatric obesity—Long‐term consequences and effect of weight loss
Marcus, C., Danielsson, P., & Hagman, E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13547 · Cited by 267
Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance
Apostolopoulou, M., Lambadiari, V., Roden, M., & Dimitriadis, G. D. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnae032 · Cited by 90
Fröhlich‐Reiterer, E., Elbarbary, N. S., Simmons, K., Buckingham, B., Humayun, K. N., Johannsen, J., Holl, R. W., Betz, S., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13445 · Cited by 74
Metadata
- Authors
- Ferrara-Cook, C., Geyer, S. M., Evans-Molina, C., Libman, I. M., Becker, D. J., Gitelman, S. E., Redondo, M. J., & the Type 1 Diabetes TrialNet Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-14
- Volume
- 43
- Issue
- 3
- Pages
- 580-587
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2999552291
- Cited by
- 65
- References
- 10
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. https://app.cochat.ai/papers/10.2337/dc19-1167
- The paper
- Ferrara-Cook, C., Geyer, S. M., Evans-Molina, C., Libman, I. M., Becker, D. J., Gitelman, S. E., Redondo, M. J., & the Type 1 Diabetes TrialNet Study Group. (2020). Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care. https://doi.org/10.2337/dc19-1167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.